New 'Living Drug' trial offers hope for Tough-to-Treat lymphoma
NCT ID NCT06875063
Summary
This study is testing the safety and early effectiveness of an experimental treatment called GB5005 for adults with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or hasn't responded to standard therapies. GB5005 is a type of CAR-T therapy, where a patient's own immune cells are modified in a lab to better find and fight cancer cells, then infused back into the patient. The main goals are to see how safe the treatment is and if it can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bing Xu
RECRUITINGXiamen, Fujian, 361000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.